Pharmacotherapy for the treatment of vaginal atrophy.

abstract：:The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...

journal_title：Expert opinion on pharmacotherapy

authors： Lunnon MW

更新日期：2000-03-01 00:00:00

abstract：INTRODUCTION:Stiripentol and vigabatrin are the two anticonvulsant drugs currently approved in severe infantile-onset epilepsies, respectively Dravet syndrome and infantile spasms. AREAS COVERED:For both, the indication was discovered by chance thanks to an exploratory study. Both demonstrated indisputable efficacy th...

journal_title：Expert opinion on pharmacotherapy

authors： Chiron C

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of int...

journal_title：Expert opinion on pharmacotherapy

authors： Frandsen CS,Dejgaard TF,Madsbad S,Holst JJ

更新日期：2018-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

journal_title：Expert opinion on pharmacotherapy

authors： Bertelli G,Gangadhara S

更新日期：2010-08-01 00:00:00

abstract：:There is considerable controversy over the level of evidence from randomized trials underpinning management decisions for patients presenting with localized cancer of the esophagus and esophago-gastric junction. There is also an optimism that new drugs and new approaches, including response prediction based on sequent...

journal_title：Expert opinion on pharmacotherapy

authors： Murphy TJ,Ravi N,Reynolds JV

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

journal_title：Expert opinion on pharmacotherapy

authors： Stirnimann G

更新日期：2014-12-01 00:00:00

abstract：:Alpha-1 antitrypsin (AAT) deficiency is an under-recognized genetic condition that predisposes to liver disease and early-onset emphysema. Although AAT is mainly produced in the liver, its main function is to protect the lung against proteolytic damage from neutrophil elastase. The most common mutation responsible for...

journal_title：Expert opinion on pharmacotherapy

authors： Modrykamien A,Stoller JK

更新日期：2009-11-01 00:00:00

abstract：BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

journal_title：Expert opinion on pharmacotherapy

authors： Dunn J,Lovat L

更新日期：2008-04-01 00:00:00

abstract：:Despite the revolutionary introduction of antibiotic therapy in the post-World War II era, primary care physicians continue to struggle with the issue of optimal treatment strategies for bacterial infection and the growing problem of antimicrobial resistance. The aggressive use of potent agents as first-line therapy m...

journal_title：Expert opinion on pharmacotherapy

authors： Nicolau DP

更新日期：2004-02-01 00:00:00

abstract：:Somatropin (rDNA origin) injection (Zorbtive) is a highly purified preparation of human growth hormone (GH) produced from a mammalian cell line by recombinant DNA technology. It is the only human GH approved for the treatment of short bowel syndrome in patients receiving specialised nutritional support. The process of...

journal_title：Expert opinion on pharmacotherapy

authors： Matarese LE,Abu-Elmagd K

更新日期：2005-08-01 00:00:00

abstract：:ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

journal_title：Expert opinion on pharmacotherapy

authors： Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

更新日期：2021-01-04 00:00:00

abstract：INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

journal_title：Expert opinion on pharmacotherapy

authors： Tecilazich F,Dinh T,Veves A

更新日期：2011-03-01 00:00:00

abstract：INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...

journal_title：Expert opinion on pharmacotherapy

authors： Guan YS,He Q

更新日期：2011-02-01 00:00:00

abstract：INTRODUCTION:During recent decades, the prognosis of childhood acute lymphoblastic leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90%. These results are due to a better management and combination of old therapies, refined risk-group stratification and emergence of minimal residual di...

journal_title：Expert opinion on pharmacotherapy

authors： Santiago R,Vairy S,Sinnett D,Krajinovic M,Bittencourt H

更新日期：2017-08-01 00:00:00

abstract：INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...

journal_title：Expert opinion on pharmacotherapy

authors： Panza F,Lozupone M,Watling M,Imbimbo BP

更新日期：2020-10-06 00:00:00

abstract：:Antiplatelet therapy is the cornerstone of treatment for patients who present with acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI). Clopidogrel, in combination with aspirin, is associated with improvement in long-term clinical outcomes in these patients and is currently the antiplatel...

journal_title：Expert opinion on pharmacotherapy

authors： Angiolillo DJ,Suryadevara S,Capranzano P,Bass TA

更新日期：2008-11-01 00:00:00

abstract：INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

journal_title：Expert opinion on pharmacotherapy

authors： Capodanno D,Tamburino C,Dangas G

更新日期：2011-05-01 00:00:00

abstract：OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

journal_title：Expert opinion on pharmacotherapy

authors： Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

更新日期：2010-04-01 00:00:00

abstract：INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

journal_title：Expert opinion on pharmacotherapy

authors： Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

更新日期：2014-06-01 00:00:00

abstract：INTRODUCTION:Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP). AREAS COVERED:This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic...

journal_title：Expert opinion on pharmacotherapy

authors： Falcó V,Burgos J,Almirante B

更新日期：2020-04-01 00:00:00

abstract：:This editorial considers the use of the first selective oral renin inhibitor, aliskiren, in reducing angiotensin (Ang) II reactivation or aldosterone (ALDO) escape during renin-angiotensin-aldosterone system (RAAS) inhibition. RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin recep...

journal_title：Expert opinion on pharmacotherapy

authors： Athyros VG,Mikhailidis DP,Kakafika AI,Tziomalos K,Karagiannis A

更新日期：2007-04-01 00:00:00

abstract：BACKGROUND:Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE:In this articl...

journal_title：Expert opinion on pharmacotherapy

authors： Barragan P,Podzamczer D

更新日期：2008-09-01 00:00:00

abstract：INTRODUCTION:Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat. Although multiple therapeutic options are available, all have limitations. Topical preparations have issues with patient adherence, as compared to...

journal_title：Expert opinion on pharmacotherapy

authors： Shutty B,West C,Pellerin M,Feldman S

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent. AREAS CO...

journal_title：Expert opinion on pharmacotherapy

authors： Ruxandra U,Antoniu SA,Mihaltan F,Boisteanu D

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeabi...

journal_title：Expert opinion on pharmacotherapy

authors： Apte RS

更新日期：2008-02-01 00:00:00

abstract：:Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non...

journal_title：Expert opinion on pharmacotherapy

authors： Ohe Y

更新日期：2005-12-01 00:00:00

abstract：INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

journal_title：Expert opinion on pharmacotherapy

authors： Moroni G,Ponticelli C

更新日期：2017-02-01 00:00:00

abstract：BACKGROUND:Moderate hypertriglyceridemia is fairly common, and elevated triglycerides are a risk factor for coronary heart disease. The omega-3 fatty acids EPA and DHA have been shown to lower triglycerides in many clinical studies. Prescription omega-3 fatty acid concentrates (P-OM3) are indicated for use in people wi...

journal_title：Expert opinion on pharmacotherapy

authors： Skulas-Ray AC,West SG,Davidson MH,Kris-Etherton PM

更新日期：2008-05-01 00:00:00

abstract：:Although effective anti-neoplastic agents, anthracyclines are limited by their well recognized and pervasive cardiotoxic effects. The incidence of late progressive cardiovascular disease in long-term survivors of cancer is established and may contribute to heart failure and death. To maximize the benefits of these dru...

journal_title：Expert opinion on pharmacotherapy

authors： Barry E,Alvarez JA,Scully RE,Miller TL,Lipshultz SE

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:Seizures or chronic epilepsy are a relatively common occurrence in a neurosurgical setting. However, seizure treatment after neurosurgery has received less attention compared with other causes and only few data are availaible in the literature on management in neurosurgical patients. Areas covered: This pa...

journal_title：Expert opinion on pharmacotherapy

authors： Ambrosi M,Orsini A,Verrotti A,Striano P

更新日期：2017-10-01 00:00:00